Home > DNA/RNA Synthesis & > Dacarbazine

Dacarbazine

Dacarbazine是一种抗肿瘤化疗药物，用于治疗多种癌症。

目录号
EY1383
EY1383
EY1383
纯度
99.39%
99.39%
99.39%
规格
50 mg
100 mg
200 mg
原价
200
380
500
售价
200
380
500
库存
现货
现货
现货
订购
订购
订购
订购
订购
订购
具体折扣请咨询客服

  • 生物活性

    Dacarbazine is an antineoplastic chemotherapy drug used in the treatment of various cancers.

  • 体外研究

  • 体内研究

  • 激酶实验

  • 细胞实验

  • 动物实验

  • 不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数


    例如，已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法：将88 mg/kg 乘以小鼠的Km系数（3），再除以大鼠的Km系数（6），得到该药物用于大鼠的等效剂量44 mg/kg。

  • 参考文献

    [1] Masayuki Sanada et. Al. Modes of actions of two types of anti-neoplastic drugs, dacarbazine and ACNU, to induce apoptosis. Carcinogenesis, 28(12), 2657-2663 (2007).
    [2] Michiko Horiguchi et. Al. Glucocorticoid-dependent expression of O(6)-methylguanine-DNA methyltransferase gene modulates dacarbazine-induced hepatotoxicity in mice. Journal of Pharmacology and Experimental Therapeutics, 333(3), 782-787 (2010).
    [3] Brian J Wilson et. Al. ABCB5 maintains melanoma-initiating cells through a proinflammatory cytokine signaling circuit. Cancer Research, 74(15), 4196-4207 (2014).

    分子式
    C6H10N6O    		 分子量
    182.18    		 CAS号
    4342-03-4    		 储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂（常温）
    		 DMSO
    2 mg/mL    		 Water
    <1 mg/mL    		 Ethanol
    <1 mg/mL

    体内溶解度

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT Number Conditions Interventions Sponsor/Collaborators Phases Start Date Last Updated
    NCT00597038 Metastatic Melanoma Drug: Dasatinib and Dacarbazine (DTIC) H. Lee Moffitt Cancer Center and Research Institute|Bristol-Myers Squibb Phase 1|Phase 2 2007-11-01 2013-11-21
    NCT00518895 Melanoma Drug: dacarbazine plus Genasense|Drug: dacarbazine plus placebo Genta Incorporated Phase 3 2007-07-01 2011-11-04
    NCT01133977 Stage IV Melanoma Drug: Lenvatinib|Drug: Lenvatinib|Drug: Dacarbazine Eisai Inc.|Quintiles, Inc. Phase 1|Phase 2 2010-04-01 2016-08-16
    NCT00837148 Sarcoma|Synovial Sarcoma|Leiomyosarcoma|Malignant Peripheral Nerve Sheath Tumor Drug: Sorafenib and Dacarbazine Memorial Sloan Kettering Cancer Center|Bayer Phase 2 2009-02-01 2015-10-19
    NCT00492297 Melanoma Drug: Sorafenib (Nexavar, BAY43-9006) + Dacarbazine (DTIC) Bayer Phase 2 2005-04-01 2014-10-23
    NCT00354523 Solid Tumor|Thyroid Cancer Drug: Capecitabine (Xeloda)|Drug: DTIC-Dome (Dacarbazine)|Drug: Gleevec (Imatinib Mesylate) M.D. Anderson Cancer Center|Novartis Pharmaceuticals Phase 1|Phase 2 2004-12-01 2014-12-16
    NCT00802880 Sarcoma Drug: Dacarbazine Washington University School of Medicine Phase 2 2009-03-01 2016-12-20
    NCT00864253 Malignant Melanoma Drug: ABI-007|Drug: Dacarbazine Celgene Corporation|University of Arizona Phase 3 2009-04-01 2016-12-14
    NCT00580320 Melanoma|Soft Tissue Sarcoma|Parathyroid Carcinoma|Small Cell Carcinoma of the Lung|Carcinoid Tumors Drug: Dacarbazine and bortezomib Virginia Commonwealth University Phase 1 2004-09-01 2016-08-17
    NCT01055522 Metastatic Melanoma Drug: Arm 1: L19IL2 + Dacarbazine|Drug: Arm 3: Dacarbazine|Drug: ARM 2: L19IL2 + Dacarbazine Philogen S.p.A.|Eudax S.r.l. Phase 2 2008-06-01 2014-02-24
    NCT01692691 Melanoma Metastatic Drug: Dacarbazine|Drug: Carmustine|Drug: Neulasta Western Regional Medical Center Phase 2 2012-08-01 2016-05-02
    NCT01693068 N-Ras Mutated Locally Advanced or Metastasis Malignant Cutaneous Melanoma Drug: Pimasertib|Drug: Dacarbazine EMD Serono|Merck KGaA Phase 2 2012-12-01 2016-02-11
    NCT00091572 Melanoma Drug: Temozolomide|Drug: Dacarbazine Merck Sharp & Dohme Corp.|European Organisation for Research and Treatment of Cancer - EORTC Phase 3 2004-10-01 2015-04-28
    NCT01681212 Melanoma Drug: Ipilimumab|Drug: Dacarbazine Bristol-Myers Squibb Phase 2 2012-10-01 2015-06-09
    NCT00130442 Melanoma Drug: PI-88 and dacarbazine|Drug: dacarbazine or DTIC Medigen Biotechnology Corporation|Progen Pharmaceuticals Phase 2 2005-06-01 2016-03-30
    NCT00553618 Metastatic Melanoma Drug: Proleukin and Dacarbazine James Graham Brown Cancer Center|University of Louisville Phase 2 2007-08-01 2016-11-21
    NCT01551459 Metastatic Uveal Melanoma Drug: Dacarbazine|Drug: Sunitinib The Clatterbridge Cancer Centre NHS Foundation Trust|Cancer Research UK|Pfizer Phase 2 2010-10-01 2016-07-25
    NCT01763164 Metastatic or Unresectable Cutaneous Melanoma Drug: MEK162|Drug: Dacarbazine Array BioPharma Phase 3 2013-07-01 2016-09-30
    NCT00496223 Melanoma Drug: Sunitinib|Drug: Dacarbazine H. Lee Moffitt Cancer Center and Research Institute|Pfizer Phase 1|Phase 2 2006-09-01 2011-02-21
    NCT03023124 Solitary Fibrous Tumors Drug: Trabectedin|Drug: Adriamycin|Drug: Dacarbazine Italian Sarcoma Group Phase 2 2017-03-01 2017-01-26
    NCT00533702 Metastatic Malignant Melanoma Biological: IMC-1121B (ramucirumab)|Drug: Dacarbazine Eli Lilly and Company Phase 2 2007-11-01 2014-07-29
    NCT02190838 Melanoma Drug: Metformin|Drug: Melatonin|Drug: Dacarbazine Petrov Research Institute of Oncology Phase 2 2014-04-01 2016-12-29
    NCT01152788 Melanoma Drug: rIL-21|Drug: Dacarbazine NCIC Clinical Trials Group|Canadian Cancer Trials Group Phase 2 2010-06-01 2015-02-13
    NCT01343277 Advanced Liposarcoma or Leiomyosarcoma Drug: Trabectedin|Drug: Dacarbazine Janssen Research & Development, LLC|PharmaMar Phase 3 2011-06-01 2016-07-15
    NCT00324155 Melanoma Drug: Ipilimumab|Drug: Placebo|Drug: Dacarbazine Bristol-Myers Squibb|Medarex Phase 3 2006-08-01 2014-10-24

    注：以上所有数据均来自公开文献，并不保证对所有实验均有效，数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 ：
  • 收件地址 ：
  • 电话号码 ：
  • 单位名称 ：
  • 产品货号 ：
  • 产品规格 ：
  • 发票抬头以及单位税号 ：